Suppressive therapy of thyroid nodules in patients with previous radiotherapy to the head and neck.
This is a prospective, randomized study of 431 patients with palpable thyroid nodules who had previous radiotherapy for benign disorders of the head and neck area to determine the response of the thyroid nodules to suppressive therapy and the incidence of thyroid cancer in patients who could not be suppressed and had surgery. A complete response was achieved within 6 months in 18.3 percent of the patients, and in an additional 26 percent of patients between 7 and 12 months postoperatively. Twenty percent of the patients showed complete disappearance of nodules after 1 to 2 years of suppressive therapy. Twenty-two percent who underwent surgery showed carcinoma. If suppressive therapy is to be used, a trial of 1 year rather than 3 or 6 months, as often recommended, may be appropriate.
Razack
M S
MS
Department of Head and Neck Surgery and Oncology, Roswell Park Memorial Institute, Buffalo, New York 14263.
Shimaoka
K
K
Sako
K
K
Rao
U
U
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006258:Head and Neck Neoplasms / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D011446:Prospective Studies; D011897:Random Allocation; D013962:Thyroid (USP) / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D013965:Thyroidectomy; D014284:Triiodothyronine / Q000627:therapeutic use
D013962:Thyroid (USP); D014284:Triiodothyronine